Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis

Table 1 Medications taken by patients at time of infliximab treatment

Medication	UC patients (n = 15)
5-ASA
Current	93.3% (14/15)
Intolerant	6.7% (1/15)
Steroids
IV	40.0% (6/15)
PO	53.3% (8/15)
Intolerant	6.7% (1/15)
Immunomodulators
AZA/6MP	86.7% (13/15)
< 8 wk	53.3% (8/15)
≥ 8 wk	33.3% (5/15)
Intolerant	13.3% (2/15)
Tacrolimus	6.7% (1/15)
Methotrexate	6.7% (1/15)

Table 2 Individual patient data of disease extent, CAI scores pre and post infliximab, steroid usage and therapeutic immunomodulation (therapy > 8 wk at ≥ 1.5 mg/kg of 6-MP) at time of infliximab and time to colectomy

	Sex	Age at diagnosis	Age at infliximab	Disease extent	CAI at infliximab	CAI at 8 wk	On steroids IV or oral	Therapeutic immuno-modulation	Response to infliximab	Time to surgery (mo)
1	F	37	59	Pan Colitis	14	4	Intolerant	No	Complete
2	M	25	26	Pan Colitis	14	0	IV	No	Complete
3	F	28	28	Pan Colitis	11	N/A	IV	No	Partial	1
4	F	45	49	Pan Colitis	14	4	IV	No	Complete
5	F	54	54	Pan Colitis	20	6	IV	No	Partial
6	M	24	28	Pan Colitis	13	4	IV	No	Complete
7	F	22	22	Pan Colitis	11	6	IV	No	Partial
8	M	17	18	Pan Colitis	13	0	Oral	No	Complete	26
9	M	56	58	Proctitis	12	11	Oral	Yes	Nil	8
10	M	54	55	Left sided	15	N/A	Oral	Yes	Nil	< 1
11	M	32	40	Pan Colitis	10	6	Oral	Yes	Partial	12
12	M	25	31	Pan Colitis	16	3 (on steroids)	Oral	Yes	Partial	5
13	M	27	28	Pan Colitis	14	9	Oral	Yes	Partial	9
14	M	32	38	Pan Colitis	8	3 (on steroids)	Oral	Yes	Partial	9
15	M	56	40	Pan Colitis	13	1	Oral	Yes	Complete	6

Table 3 Remission and response rates at 8 wk to infliximab in the UC patients and colectomy rates at 6 mo and 12 mo

Disease type	Response	Remission	Colectomy	Colectomy
	wk 8	wk 8	≤ 6 mo	≤ 12 mo
E1 - proctitis	0%	0%	0%	100%
	(0/1)	(0/1)	(0/1)	(1/1)
E2 - left sided	0%	0%	100%	100%
	(0/1)	(0/1)	(1/1)	(1/1)
E3 - extensive	100%	46.20%	23.10%	46.10%
	(13/13)	(6/13)	(3/13)	(6/13)
Total	86.70%	40.00%	26.70%	53.30%
	(13/15)	(6/15)	(4/15)	(8/15)

Table 4 Colectomy rates at 6 mo and 12 mo compared to clinical response to infliximab

Response	No surgery	Colectomy	Colectomy
	at 12 mo	≤6 mo	≤12 mo
No response	0%	50%	100%
	(0/3)	(1/2)	(2/2)
Partial response	28.60%	28.60%	71.40%
	(2/7)	(2/7)	(5/7)
Complete response	83.30%	16.70%	20%
	(5/6)	(1/6)	(1/5)
Total	46.70%	26.70%	57.10%
	(7/15)	(3/16)	(8/14)